Publication:
Effectiveness and safety of initiation and titration of insulin glargine 300 u/ml in insulin-naive patients with type 2 diabetes mellitus uncontrolled on oral antidiabetic drug treatment in Turkey: the EASE study

Thumbnail Image

Departments

School / College / Institute

Organizational Unit
Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Cetinarslan, Berrin
Cetinkalp, Sevki
Kaya, Ahmet
Ersoy, Canan
Kebapci, Nur
Comlekci, Abdurrahman
Tutuncu, Neslihan Bascil
Oguz, Aytekin
Ilkova, Hasan
Yilmaz, Temel

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Objective: The aim of the study was to evaluate the effectiveness and safety of insulin glargine 300 U/ mL (Gla-300) in insulin-naive patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drug (OADs) treatment in Turkey. Methods: One hundred eight patients from 20 centers enrolled in the study. Starting from baseline, Gla-300 was self-administered subcutaneously and once daily in the evening. The primary outcome was the mean change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. Results: The mean (+/- SD) Hb1Ac level of 9.4% (+/- 0.8) at baseline decreased to 7.5% (+/- 0.9) at week 12 (P < .1) and to 7.3% (+/- 0.9) at week 24 (P < .1). Although none of the patients were within the target Hb1Ac level of <= 7% at baseline, the percentage of patients who achieved the target Hb1Ac level was 30.4% at week 12 and increased to 42.9% at week 24. Gla-300 treatment achieved the Hb1Ac target in 21 (19.4%) patients without experiencing a hypoglycemic event and in 27 (25.0%) patients who experienced at least one hypoglycemic event. For each self-monitoring blood glucose time point, significant improvements were observed as compared to baseline (P < .001). Statistically significant improvement (P < .001) was seen in the treatment satisfaction questionnaire - status version scores between baseline and week 24. Conclusion: This study indicated that Gla-300 is effective to provide a successful glycemic control with low risk of hypoglycemia added to OADs in insulin-naive patients with T2DM, and it has the potential to improve the quality of life of patients.

Source

Publisher

AVES

Subject

Endocrinology and metabolism

Citation

Has Part

Source

Endocrinology Research and Practice

Book Series Title

Edition

DOI

10.5152/erp.2024.23311

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

3

Views

5

Downloads

View PlumX Details